Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent SearchGlobeNewsWire • 01/21/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/09/26
Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalystsProactive Investors • 01/07/26
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & JohnsonZacks Investment Research • 01/06/26
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?Zacks Investment Research • 01/02/26
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaGlobeNewsWire • 12/23/25
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial AsthmaGlobeNewsWire • 12/23/25
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/22/25
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma TranscriptSeeking Alpha • 12/10/25
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trialReuters • 12/10/25
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline TreatmentGlobeNewsWire • 12/07/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/03/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/02/25
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATDZacks Investment Research • 12/02/25
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?Zacks Investment Research • 12/01/25
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 12/01/25